5Mowat C, Cole A, Windsor Al, et al. Guidelines for themanagement of inflammatory bowel disease in adults[J].Gut, 2011, 60:571-607.
6Van Assche G, Axel Dignass A, Panes J, et al. for theEuropean Crohn’s and Colitis Organisation (ECCO).The second European evidence-based consensuson the diagnosis and management of Crohn’sdisease:Definitions and diagnosis[J].J Crohn’s colitis,2010’ 4 (1):7-27.
7Baumgart DC, Bernstein CN, Abbas Z, et al. IBD Aroundthe World: Comparing the Epidemiology, Diagnosis, andTreatment: Proceedings of the World Digestive HealthDay 2010-lnflammatory Bowel Disease Task ForceMeetingfJ]. Inflamm Bowel Dis, 2011, 17(2): 639-644.
8Lichtenstein GR, Abreu MT, Cohen R, et al. Americangastroenterological association institute medical position statement on corticosteroids, immunomodulators, and inflixinmab in inflammato ry bowel disease[J]. Gastroenterol, 2006, 130(3):935-939, 940-987.
9Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article:treatment algorithms to maximize remission andminimize corticosteroid dependence in patients with inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2008, 28: 674-88.
10Ouakaa-Kchaou A, Gargouri D, Elloumi H, et al. Ciclosporin for severe refractory colitis[J]. Tunis Med, 2010, 88(6):390-3.
